Eligibility for Photoimmunotherapy in Patients with Unresectable Advanced or Recurrent Head and Neck Cancer and Changes before and after Systemic Therapy
Photoimmunotherapy is a novel cancer treatment that recently became covered by national health insurance in Japan, but treatment decision-making remains challenging for unresectable advanced or recurrent head and neck cancer. We aimed to clarify the characteristics of patients for whom photoimmunoth...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2023-07-01
|
| Series: | Cancers |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2072-6694/15/15/3795 |
| _version_ | 1797587012731011072 |
|---|---|
| author | Takeshi Shinozaki Kazuto Matsuura Wataru Okano Toshifumi Tomioka Yukio Nishiya Michiko Machida Ryuichi Hayashi |
| author_facet | Takeshi Shinozaki Kazuto Matsuura Wataru Okano Toshifumi Tomioka Yukio Nishiya Michiko Machida Ryuichi Hayashi |
| author_sort | Takeshi Shinozaki |
| collection | DOAJ |
| description | Photoimmunotherapy is a novel cancer treatment that recently became covered by national health insurance in Japan, but treatment decision-making remains challenging for unresectable advanced or recurrent head and neck cancer. We aimed to clarify the characteristics of patients for whom photoimmunotherapy was indicated by a retrospective chart review. Patients aged ≥20 years diagnosed with advanced or recurrent head and neck cancer who started receiving systemic therapy at the National Cancer Center Hospital East from January 2016 through December 2020 were retrospectively analyzed. Before and after first-line systemic therapy, patients were classified into 3 groups according to eligibility for photoimmunotherapy: eligible, potentially eligible, and ineligible. In total, of 246 patients evaluated—194 after exclusions were analyzed—108 were deemed ineligible for treatment. Of the remaining 86 patients, 8 were considered potentially eligible and 9 eligible. Of the nine eligible patients, four became ineligible after receiving first-line systemic therapy due to disease progression. Our results suggest that the indication of photoimmunotherapy should be considered before, during, and after systemic therapy for unresectable locally advanced or recurrent head and neck cancer. |
| first_indexed | 2024-03-11T00:30:14Z |
| format | Article |
| id | doaj.art-4f9d6b742aa54722a2019bac20bfa91a |
| institution | Directory Open Access Journal |
| issn | 2072-6694 |
| language | English |
| last_indexed | 2024-03-11T00:30:14Z |
| publishDate | 2023-07-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Cancers |
| spelling | doaj.art-4f9d6b742aa54722a2019bac20bfa91a2023-11-18T22:41:31ZengMDPI AGCancers2072-66942023-07-011515379510.3390/cancers15153795Eligibility for Photoimmunotherapy in Patients with Unresectable Advanced or Recurrent Head and Neck Cancer and Changes before and after Systemic TherapyTakeshi Shinozaki0Kazuto Matsuura1Wataru Okano2Toshifumi Tomioka3Yukio Nishiya4Michiko Machida5Ryuichi Hayashi6Department of Head and Neck Surgery, National Cancer Center Hospital East, Kashiwa 277-8577, JapanDepartment of Head and Neck Surgery, National Cancer Center Hospital East, Kashiwa 277-8577, JapanDepartment of Head and Neck Surgery, National Cancer Center Hospital East, Kashiwa 277-8577, JapanDepartment of Head and Neck Surgery, National Cancer Center Hospital East, Kashiwa 277-8577, JapanDepartment of Head and Neck Surgery, National Cancer Center Hospital East, Kashiwa 277-8577, JapanMedical Science & Operations Division, Rakuten Medical K.K., Tokyo 158-0094, JapanDepartment of Head and Neck Surgery, National Cancer Center Hospital East, Kashiwa 277-8577, JapanPhotoimmunotherapy is a novel cancer treatment that recently became covered by national health insurance in Japan, but treatment decision-making remains challenging for unresectable advanced or recurrent head and neck cancer. We aimed to clarify the characteristics of patients for whom photoimmunotherapy was indicated by a retrospective chart review. Patients aged ≥20 years diagnosed with advanced or recurrent head and neck cancer who started receiving systemic therapy at the National Cancer Center Hospital East from January 2016 through December 2020 were retrospectively analyzed. Before and after first-line systemic therapy, patients were classified into 3 groups according to eligibility for photoimmunotherapy: eligible, potentially eligible, and ineligible. In total, of 246 patients evaluated—194 after exclusions were analyzed—108 were deemed ineligible for treatment. Of the remaining 86 patients, 8 were considered potentially eligible and 9 eligible. Of the nine eligible patients, four became ineligible after receiving first-line systemic therapy due to disease progression. Our results suggest that the indication of photoimmunotherapy should be considered before, during, and after systemic therapy for unresectable locally advanced or recurrent head and neck cancer.https://www.mdpi.com/2072-6694/15/15/3795photoimmunotherapyadvanced head and neck cancertiming of photoimmunotherapy |
| spellingShingle | Takeshi Shinozaki Kazuto Matsuura Wataru Okano Toshifumi Tomioka Yukio Nishiya Michiko Machida Ryuichi Hayashi Eligibility for Photoimmunotherapy in Patients with Unresectable Advanced or Recurrent Head and Neck Cancer and Changes before and after Systemic Therapy Cancers photoimmunotherapy advanced head and neck cancer timing of photoimmunotherapy |
| title | Eligibility for Photoimmunotherapy in Patients with Unresectable Advanced or Recurrent Head and Neck Cancer and Changes before and after Systemic Therapy |
| title_full | Eligibility for Photoimmunotherapy in Patients with Unresectable Advanced or Recurrent Head and Neck Cancer and Changes before and after Systemic Therapy |
| title_fullStr | Eligibility for Photoimmunotherapy in Patients with Unresectable Advanced or Recurrent Head and Neck Cancer and Changes before and after Systemic Therapy |
| title_full_unstemmed | Eligibility for Photoimmunotherapy in Patients with Unresectable Advanced or Recurrent Head and Neck Cancer and Changes before and after Systemic Therapy |
| title_short | Eligibility for Photoimmunotherapy in Patients with Unresectable Advanced or Recurrent Head and Neck Cancer and Changes before and after Systemic Therapy |
| title_sort | eligibility for photoimmunotherapy in patients with unresectable advanced or recurrent head and neck cancer and changes before and after systemic therapy |
| topic | photoimmunotherapy advanced head and neck cancer timing of photoimmunotherapy |
| url | https://www.mdpi.com/2072-6694/15/15/3795 |
| work_keys_str_mv | AT takeshishinozaki eligibilityforphotoimmunotherapyinpatientswithunresectableadvancedorrecurrentheadandneckcancerandchangesbeforeandaftersystemictherapy AT kazutomatsuura eligibilityforphotoimmunotherapyinpatientswithunresectableadvancedorrecurrentheadandneckcancerandchangesbeforeandaftersystemictherapy AT wataruokano eligibilityforphotoimmunotherapyinpatientswithunresectableadvancedorrecurrentheadandneckcancerandchangesbeforeandaftersystemictherapy AT toshifumitomioka eligibilityforphotoimmunotherapyinpatientswithunresectableadvancedorrecurrentheadandneckcancerandchangesbeforeandaftersystemictherapy AT yukionishiya eligibilityforphotoimmunotherapyinpatientswithunresectableadvancedorrecurrentheadandneckcancerandchangesbeforeandaftersystemictherapy AT michikomachida eligibilityforphotoimmunotherapyinpatientswithunresectableadvancedorrecurrentheadandneckcancerandchangesbeforeandaftersystemictherapy AT ryuichihayashi eligibilityforphotoimmunotherapyinpatientswithunresectableadvancedorrecurrentheadandneckcancerandchangesbeforeandaftersystemictherapy |